<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379157</url>
  </required_header>
  <id_info>
    <org_study_id>MISP 39337</org_study_id>
    <nct_id>NCT01379157</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics Study of Imipenem in Patients With Ventilator Associated Pneumonia</brief_title>
  <official_title>The Pharmacodynamics of Imipenem in Critically Ill Patients With Ventilator-associated Pneumonia Following Administration by 4 h or 0.5 h Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Prince of Songkla University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Imipenem is a carbapenem antibacterial agent with a broad spectrum of activity against
      Gram-negative and Gram-positive bacteria. This agent is often used as the last line of
      therapy for highly resistant Gram negative bacilli nosocomial infections. In common with
      other beta-lactamase inhibitor, the main pharmacokinetic/pharmacodynamic (PK/PD) index that
      correlates with the therapeutic efficacy is the time that concentrations in the tissue and
      serum are above the MIC and administration by continuous infusion is the preferred mode of
      administration to maximize this parameter.

      However, in tropical countries, the stability of carbapenem antibiotics is an important
      consideration when considering continuous infusion. Therefore, prolonged infusion may be a
      useful mode of administration to maximize bactericidal activity. This study will demonstrate
      the stability of imipenem in clinical use at room temperature in tropical countries.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accessed PK/PD parameters</measure>
    <time_frame>24 hours profile after first dose of trail drug.</time_frame>
    <description>- To determine plasma Imipenem PK/PD parameters (the PK/PD index (T&gt;MIC), the probability of target attainment (PTA) at 40% (T&gt;MIC), the cumulative fraction of response (CFR))after 4 hr infusion of 1 gm every 8 hr compared to 0.5 hr infusion of 0.5 gm every 6 hr.
Conventional arm: after first dose, blood samples will be obtained by direct venepuncture at: time 0, 0.5, 6, 6.5, 12, 12.5, 18, 18.25, 18.5, 18.75, 20, 21, 22 and 24 hr Extended infusion arm: after first dose, blood samples will be obtained by direct venepuncture at: time 0, 4, 8, 12, 16, 16.5, 17, 18, 20, 20.5, 21, 22, and 24 hr</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Ventilator Associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>Conventional arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of 0.5 g of imipenem for 0.5 hr every 6 hr for 3-5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended infusion arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of 1 g of imipenem for 4 hr every 8 hr for 3-5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem</intervention_name>
    <description>Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 0.5 hr infusion of 0.5 g every 6 hr of imipenem at room temperature</description>
    <arm_group_label>Conventional arm</arm_group_label>
    <other_name>Tienam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem</intervention_name>
    <description>Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 4 hr infusion of 1 g every 8 hr of imipenem at room temperature</description>
    <arm_group_label>Extended infusion arm</arm_group_label>
    <other_name>Tienam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged &gt; or = 20 years

          -  Patients who have VAP with Gram negative bacilli infections which are sensitive to
             imipenem by the disk diffusion

        Exclusion Criteria:

          -  Patients who have documented hypersensitivity to imipenem or other carbapenems

          -  Patients who have an estimated creatinine clearance of &lt; or = 60 ml/min

          -  Patients who are in circulatory shock

          -  Patients who are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine, Prince of Songkla University</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>June 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prince of Songkla University</investigator_affiliation>
    <investigator_full_name>Sutep Jaruratanasirikul</investigator_full_name>
    <investigator_title>Prof.Dr.Sutep Jaruratanasirikul</investigator_title>
  </responsible_party>
  <keyword>Patients with ventilator-associated pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

